These findings suggest varied psychiatric risks associated with different GLP-1 RA medications, with Wegovy demonstrating the highest risk for conditions such as major depressive disorder and anxiety
Some researchers explore microdosing tirzepatide at levels below the standard starting dose, though this approach falls outside typical prescribing guidelines
The evolving story of incretins (GIP and GLP 1) in metabolic and cardiovascular disease: a pathophysiological update
Another second-line pharmacologic option is prucalopride, a 5-HT4 serotoninergic agonist, with an established dose applied orally every 24 hours.94,97 Prucalopride is a good option in patients that experience adverse effects related to GLP-1 agonists because it increases gastric emptying, augmenting rectal sensitivity and intestinal transit
95%CI: 0.800.93) as well as in terms of the three individual components (cardiovascular death, myocardial infarction, and stroke)
The role of central glucagonlike peptide1 in mediating the effects of visceral illness: Differential effects in rats and mice